Centanafadine is an investigational, once-daily extended-release capsule developed by Otsuka Pharmaceutical. It is classified as a first-in-class norepinephrine, dopamine, and serotonin reuptake inhibitor (NDSRI), meaning it simultaneously increases the availability of all three neurotransmitters by blocking their reabsorption in the brain. The FDA accepted the New Drug Application for centanafadine in January 2026 and granted it priority review status, which the agency reserves for therapies that may offer meaningful advantages over existing treatments. The Prescription Drug User Fee Act (PDUFA) target action date is July 24, 2026.

The medication is being reviewed for use in children, adolescents, and adults, making it one of the few ADHD drug candidates to have been evaluated across the full age spectrum in pivotal trials.

Most ADHD medications, including common stimulants, work by boosting two brain chemicals: dopamine and norepinephrine. These chemicals help the brain stay focused and in control. That approach works well for many people.

Centanafadine does the same thing but adds a third chemical: serotonin. No other approved ADHD medication is designed to target all three at once.

Why does that matter? Serotonin plays a role in mood, emotional reactions, and sleep; areas where some people with ADHD may experience challenges. A medication that targets all three pathways could potentially help not just with focus and impulse control, but also with mood swings and racing thoughts at 2am.

Centanafadine is also a non-stimulant ADHD medication. Some clinicians have noted that the serotonergic effect could potentially reduce anxiety and irritability that patients may experience from stimulant medications. However, the FDA review process will continue to evaluate the full evidence base.

Four large clinical trials tested centanafadine in children, teens, and adults. The results were published in respected medical journals including Pediatrics Open Science and the Journal of the American Academy of Child and Adolescent Psychiatry.

Across all age groups, people taking the higher dose of centanafadine had significantly fewer ADHD symptoms than those taking a placebo. In kids, improvements showed up as early as the first week – a timeline more commonly associated with stimulant-class drugs. The results were seen in teens and adults too.

Reported side effects were mostly mild. Kids and teens most often experienced decreased appetite, nausea, or fatigue. Adults most commonly reported decreased appetite and headache. These are side effects that some ADHD medications share, but the overall picture looked manageable.

One thing that has stood out to many clinicians: the trial data suggested a lower abuse potential. That is a meaningful detail at a time when stimulant misuse and diversion are ongoing concerns.

Any medication decision needs to happen with a licensed provider who knows your history. But based on early research findings, some groups may have more interest in following centanafadine’s progress.

• People who have tried stimulants and stopped because of anxiety, mood changes, or sleep problems. If those side effects are connected to what serotonin does, a medication that works on that pathway might feel different.
• People who have both ADHD and anxiety or depression. Because serotonin plays a role in mood, there is early thinking that centanafadine could help across those conditions too. More research is needed, but it is an area of particular interest for psychiatrists treating complex cases.
• People who are cautious about stimulants due to past substance use. The low abuse-potential finding from the trials could make this a more comfortable option for that group.

For now, centanafadine is still under review and not yet available. The FDA decision is expected July 24, 2026. If you are currently navigating your ADHD treatment options and wondering whether something like this might apply to you, the best step is to talk to a licensed provider who keeps up with the latest research.

Centanafadine represents a new pharmacological approach to ADHD, one that targets three neurotransmitter systems rather than the two that most existing medications prioritize. The Phase 3 evidence supporting its FDA application spans all major age groups and shows both efficacy and a low abuse-potential profile, which distinguishes it from the stimulant medications that currently dominate ADHD pharmacotherapy.

Whether and how centanafadine changes clinical practice will depend on the outcome of the FDA review, post-approval prescribing patterns, and real-world patient outcomes over time. What is clear now is that patients and clinicians who have been looking for alternatives to traditional stimulant-based treatment have a new potential treatment to follow closely as the July 2026 decision date approaches.

Centanafadine is an investigational medication and has not been approved by the U.S. Food and Drug Administration (FDA). Its safety and effectiveness have not yet been established, and it is not currently available for prescription. Medications are prescribed only when clinically appropriate and must be taken only as directed by a licensed provider.